Sign In
Buy GENE
$0.765
+0 (+0%)
At Close: Jan 15, 2025
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
08:21am, Wednesday, 11'th Dec 2024
On Tuesday, Spruce Biosciences, Inc. SPRB revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.
Microbix Assisting EMQN with Novel Genetic-Test EQA Program
07:00am, Tuesday, 10'th Dec 2024
For Rapid Identification of Patients Susceptible to Antibiotic-Induced Hearing Loss For Rapid Identification of Patients Susceptible to Antibiotic-Induced Hearing Loss
ALS Canada announces first-of-its-kind National ALS Genetic Counsellor with funding from TD Bank Group
09:00am, Thursday, 14'th Nov 2024
The initiative will provide virtual support to Canadians affected by ALS nationwide through genetic counselling, connecting people to local genetic experts, and providing education on ALS genetics The
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomy
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
11:11am, Tuesday, 29'th Oct 2024
GeneDx Holdings WGS stock is trading higher on Tuesday.
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
11:07am, Thursday, 17'th Oct 2024
On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
09:00am, Tuesday, 15'th Oct 2024
Myriad's MyRisk® test is the first hereditary cancer test integrated into Flatiron's OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in ge
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 11'th Oct 2024
ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies Limited (Nasdaq:GENE)(ASX:GTG) on the RedChip Small Stocks,
XORTX Initiates Precision Medicine Program
05:00am, Wednesday, 09'th Oct 2024
Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism Pioneering Research Indicating a Role for Genetic Regulation of
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
08:30am, Monday, 30'th Sep 2024
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
08:00am, Wednesday, 25'th Sep 2024
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
07:30am, Wednesday, 25'th Sep 2024
Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics Provides 23andMe+ Premium members with insight into their likelihood of ex
